Opthea to Present OCS-01 Data at EURETINA Congress
Ticker: OPTEY · Form: 6-K · Filed: Sep 10, 2024 · CIK: 1815620
Sentiment: neutral
Topics: clinical-data, biotech, conference
TL;DR
Opthea presenting OCS-01 data at EURETINA Congress this month, could be big for eye disease treatments.
AI Summary
Opthea Limited announced a significant presence at the 24th EURETINA Congress and EURETINA Innovation Spotlight, taking place in September 2024. The company will present data on its novel biologic therapy, OCS-01, for the treatment of retinal diseases. This includes presentations on OCS-01's efficacy and safety profile in conditions like wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
Why It Matters
Opthea's participation highlights progress in its OCS-01 therapy, potentially impacting the treatment landscape for millions suffering from retinal diseases.
Risk Assessment
Risk Level: medium — The company is presenting clinical data, which could be positive or negative, and its success hinges on regulatory approvals and market adoption.
Key Players & Entities
- Opthea Limited (company) — Registrant
- OCS-01 (drug) — Novel biologic therapy
- 24th EURETINA Congress (event) — Conference where data will be presented
- EURETINA Innovation Spotlight (event) — Conference where data will be presented
- September 2024 (date) — Time of the EURETINA Congress
FAQ
What specific data will Opthea present at the 24th EURETINA Congress?
Opthea will present data on its novel biologic therapy, OCS-01, focusing on its efficacy and safety profile for retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
When is the 24th EURETINA Congress scheduled to take place?
The 24th EURETINA Congress is scheduled to take place in September 2024.
What is the primary focus of Opthea's presence at the EURETINA events?
Opthea's primary focus is to showcase data and advancements related to its OCS-01 therapy for retinal diseases.
What is the SEC filing form type?
The SEC filing form type is a 6-K.
What is the company's principal executive office address?
The company's principal executive office is located at Level 4, 650 Chapel Street, South Yarra, Victoria, 3141, Australia.
Filing Stats: 156 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2024-09-10 06:06:09
Filing Documents
- opt_announces_euretina.htm (6-K) — 23KB
- opt-ex99_1.htm (EX-99.1) — 33KB
- img260626642_0.jpg (GRAPHIC) — 61KB
- img260626642_1.jpg (GRAPHIC) — 61KB
- 0000950170-24-104906.txt ( ) — 225KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 09/10/2024